SG11201509665XA - Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells - Google Patents
Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cellsInfo
- Publication number
- SG11201509665XA SG11201509665XA SG11201509665XA SG11201509665XA SG11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA
- Authority
- SG
- Singapore
- Prior art keywords
- tacrolimus
- treating diseases
- neuronal cells
- protein aggregate
- diseases characterised
- Prior art date
Links
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title 1
- 230000008021 deposition Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000002569 neuron Anatomy 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 229960001967 tacrolimus Drugs 0.000 title 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1309375.2A GB201309375D0 (en) | 2013-05-24 | 2013-05-24 | Medical methods and compounds for medical use |
| PCT/GB2014/051570 WO2014188197A1 (en) | 2013-05-24 | 2014-05-22 | Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509665XA true SG11201509665XA (en) | 2015-12-30 |
Family
ID=48784691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509665XA SG11201509665XA (en) | 2013-05-24 | 2014-05-22 | Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160296500A1 (en) |
| EP (1) | EP3003304A1 (en) |
| JP (2) | JP2016528171A (en) |
| KR (1) | KR20160012184A (en) |
| CA (1) | CA2910006A1 (en) |
| GB (1) | GB201309375D0 (en) |
| SG (1) | SG11201509665XA (en) |
| WO (1) | WO2014188197A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201600376D0 (en) * | 2016-01-08 | 2016-02-24 | Chronos Therapeutics Ltd | Novel therapeutic agents |
| CN110869054B (en) * | 2017-07-04 | 2022-06-07 | 比诺斯生物科技有限公司 | Use of macrocyclic azapyridinylcyclophane metal complexes in the treatment of disease |
| US10752642B1 (en) | 2019-04-30 | 2020-08-25 | George Mason University | Macrocyclic lactones |
| US11666560B2 (en) | 2020-09-24 | 2023-06-06 | George Mason University | Anti-fibrotic agent |
| JPWO2023085363A1 (en) * | 2021-11-12 | 2023-05-19 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2279006A (en) * | 1993-06-03 | 1994-12-21 | Fujisawa Pharmaceutical Co | Treatment of amyotrophic lateral sclerosis |
| FR2810995A1 (en) * | 2000-06-29 | 2002-01-04 | Exonhit Therapeutics Sa | COMPOSITIONS AND METHODS FOR THE TREATMENT OR DETECTION OF NEURODEGENERATIVE CONDITIONS |
| AR035411A1 (en) * | 2000-12-29 | 2004-05-26 | Fujisawa Pharmaceutical Co | USE OF A TACROLIMUS DERIVATIVE TO MANUFACTURE A NEUROTROPHIC AGENT, COMPOSITIONS AND MANUFACTURING ITEMS OR KITS THAT UNDERSTAND IT, METHOD FOR MANUFACTURING AN AGENT THAT UNDERSTANDS AND FABRICS AND GRAINTS WITH A NERVOUS CELL TREATED WITH THIS COMPOSITE |
| GB0410101D0 (en) * | 2004-05-06 | 2004-06-09 | Leuven K U Res & Dev | Parkinson's disease |
| EP1810675A1 (en) * | 2006-01-18 | 2007-07-25 | Institut Curie | Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421 |
| WO2008122038A1 (en) * | 2007-04-02 | 2008-10-09 | President And Fellows Of Harvard College | Regulating autophagy |
| JP2012171895A (en) * | 2011-02-18 | 2012-09-10 | Nagoya City Univ | Therapeutic agent for ataxia telangiectasia and application of the same |
-
2013
- 2013-05-24 GB GBGB1309375.2A patent/GB201309375D0/en not_active Ceased
-
2014
- 2014-05-22 CA CA2910006A patent/CA2910006A1/en not_active Abandoned
- 2014-05-22 EP EP14726740.5A patent/EP3003304A1/en not_active Withdrawn
- 2014-05-22 SG SG11201509665XA patent/SG11201509665XA/en unknown
- 2014-05-22 US US14/893,181 patent/US20160296500A1/en not_active Abandoned
- 2014-05-22 WO PCT/GB2014/051570 patent/WO2014188197A1/en not_active Ceased
- 2014-05-22 KR KR1020157036082A patent/KR20160012184A/en not_active Withdrawn
- 2014-05-22 JP JP2016514483A patent/JP2016528171A/en active Pending
-
2019
- 2019-02-15 JP JP2019025307A patent/JP2019104746A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016528171A (en) | 2016-09-15 |
| WO2014188197A1 (en) | 2014-11-27 |
| US20160296500A1 (en) | 2016-10-13 |
| CA2910006A1 (en) | 2014-11-27 |
| GB201309375D0 (en) | 2013-07-10 |
| JP2019104746A (en) | 2019-06-27 |
| EP3003304A1 (en) | 2016-04-13 |
| KR20160012184A (en) | 2016-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267609B (en) | Bet protein inhibitors in combination with janus kinase inhibitors for the treatment of proliferative diseases | |
| LT3542798T (en) | Aceclidine for use in the treatment of presbyopia | |
| ZA201603332B (en) | Gla monotherapy for use in cancer treatment | |
| HUE068364T2 (en) | Factor 1 protein for use in treating or preventing diseases | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| PL3060237T3 (en) | Modified reprogramming protein for use in treating a cancer | |
| EP2991670B8 (en) | Sobetirome in the treatment of myelination diseases | |
| SMT202000164T1 (en) | Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities | |
| SG11201505460WA (en) | Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations | |
| EP2849785A4 (en) | Methods for treating cancer with notch2/3 antibodies | |
| EP2904014A4 (en) | Alternative pathway specific antibodies for treating hemolytic diseases | |
| IL232791A0 (en) | Methods for the treating hyperbilirubinemia with stannsoporfin | |
| IL274047B (en) | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein | |
| IL245541A0 (en) | Novel methods for treating neurodegenerative diseases | |
| SG11201509665XA (en) | Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells | |
| IL236714A0 (en) | Anri-her2 antibodies with low fucosylation for use in treating cancer | |
| IL239078A0 (en) | Protein for use in the treatment of ocular diseases | |
| PT2836176T (en) | Technique for treating presbyopia | |
| IL236505B (en) | Enoxacin for use in treating motor neuron diseases | |
| ZA201302565B (en) | Methods for treating hyperuricemia and related diseases | |
| HK1228736A1 (en) | Novel methods for treating neurodegenerative diseases | |
| HUE048942T2 (en) | Anthracyline derivatives for treating tumor diseases |